{"acquisitions":[],"changes":[],"country":"US","description":"Ambros Therapeutics is a clinical-stage biotech advancing neridronate, a non-opioid bisphosphonate, through Phase 3 for complex regional pain syndrome type 1. It serves CRPS-1 patients facing severe unrelenting pain with no FDA-approved drugs available. Backed by RA Capital and Enavate Sciences.","domain":"ambrosrx.com","employees":null,"founded":2024,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","industrySources":[],"investors":[],"lat":23.129195,"lng":113.270205,"location":"1-10","multiples":[],"name":"Ambros Therapeutics","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":125000000,"connectionsAmong":[],"currency":"USD","date":"2025-12-01","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"ambrosrx-com-2025-12-01-series-a","source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-16","status":"attributed","url":null},"status":"attributed","type":"series-a","url":null}],"slug":"ambrosrx-com","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-16","status":"attributed","url":null},{"fact":"existence","publisher":"ambrosrx.com","retrievedAt":"2026-05-16","status":"self-reported","url":"https://ambrosrx.com"},{"fact":"description","publisher":"ambrosrx.com","retrievedAt":"2026-05-16","status":"self-reported","url":"https://ambrosrx.com"}],"stage":"series-a","stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":[],"totalRaisedUsd":154000000,"traction":[],"updatedAt":"2026-05-16","valuations":[]}